Ispitivanje kompatibilnosti nateglinida s pomoćnim tvarima u razvoju tableta nateglinida za trenutno oslobađanje by NIHAR RANJAN PANI et al.
Incompatibility between drugs and excipients can alter drug stability and bioavaila-
bility and thereby affect their safety and efficacy. Study of drug-excipient compatibility
is an important process in the early development stage of stable solid dosage forms.
However, no universally accepted protocol is available for evaluating the drug compati-
bility with different excipients (1). The few reported methods generally used for such
studies have poor predictive values and some are laborious and time consuming. Differ-
ential scanning calorimetry (DSC) is widely used for evaluating the drug-excipient inter-
action (2–7). Though it has well documented advantages, such as requirement of small
sample size and rapid results, exposure of drug-excipient mixture to high temperature
(300 °C or more) may deteriorate some of the excipients used. The DSC results should be
interpreted carefully, since the conclusions based on the DSC results alone can often be
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Experiments were done to assess the compatibility of
nateglinide with selected excipients in the development
of immediate release tablets of nateglinide by thermal
and isothermal stress testing (IST) techniques. To evalu-
ate the drug-excipient compatibility, different techniques
such as differential scanning calorimetric (DSC) study,
infra-red (IR) spectrophotometric study and isothermal
stress testing were adopted. The results of DSC study
showed that magnesium stearate exhibited some interac-
tion with nateglinide. However, the results of IR, and
IST studies showed that all the excipients used in the
formula were compatible with nateglinide. Optimized
formulations developed using the compatible excipients
were found to be stable over 3 months of accelerated sta-
bility studies (40 ± 2 °C and 75 ± 5 % RH). Overall, com-
patibility of excipients with nateglinide was successfully
evaluated using a combination of thermal and IST meth-
ods and the formulations developed using the compati-
ble excipients were found to be stable.
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misleading and inconclusive (4, 6). Isothermal stress testing (IST) involves storage of
drug-excipient blends with or without moisture at elevated temperature (> 50 °C) for a
specific period of time (normally 3–4 weeks) to accelerate drug ageing and its interac-
tion with excipients. IST has specific application in pharmaceutical industry where the
interaction between drug and excipients is visually observed and the drug content is de-
termined quantitatively (1, 4, 8, 9). However, the disadvantage of this method is that it
is time consuming and laborious. Ideally, both techniques, DSC and IST, should be used
in combination during compatibility studies for the selection of excipients.
Nateglinide (NTG), a meglitinide derivative, is mainly indicated for the treatment
of type-2 diabetics (10). In the present study, DSC, IR and IST were used for the selection
of excipients used in the development of immediate release formulations of NTG. In re-
cent years, despite the increasing interest in controlled release drug delivery systems,
scientists are paying more attention to developing effective formulations for the poorly
soluble drugs, which easily disintegrate and dissolve the active species rapidly in the
GIT for better bioavailability. Bioavailability of the poorly soluble drugs from the solid




Nateglinide (purity 99.6 %), a gift sample from Glenmark Pharmaceutical Limited,
India, was characterized against the working standard of NTG (purity 99.7 %), which
was obtained as a gift sample from Novartis Pharmaceutical, USA. The following chemi-
cals and excipients were purchased from commercial sources and used as such: lactose
(Libraw Pharma, India), microcrystalline cellulose (Avicel PH-101, FMC, USA), croscar-
mellose sodium (Ac-Di-Sol, Maple Biotech, India), L-hidroxypropyl cellulose (Hypro-
lose, Zheijiang Joinway Pharm, China), Polacrilin K (Kyron T314, Corel Pharm, India),
polyvinylpyrrolidone (Plasdone K-30, ISP, USA) and magnesium stearate (Mallinckrodt,
USA).
Methanol and acetonitrile used for the preparation of mobile phase were of HPLC
grade (Ranbaxy, India) and water used throughout the HPLC analysis was prepared
with a water purifier (Arium, 611UF, Sartorius, Germany).
Methods
Differential scanning calorimetry. – A differential scanning calorimeter (JADE DSC,
Perkin Elmer, USA) was used for thermal analysis of the drug and mixtures of drug and
excipients. Excipients expected to be used in the development of immediate release tab-
lets of NTG at an appropriate ratio were selected for the study. Individual samples of the
drug and excipients as well as physical mixtures of the drug and selected excipients were
weighed directly into the DSC aluminum crucible (Table I) and scanned in the tempera-
ture range of 50–300 °C under a dry nitrogen atmosphere. The heating rate was 20 °C
min–1 and the thermograms obtained were observed for interactions.
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IR spectroscopy. – IR spectra of the drug and a blend of drug and selected excipient
were recorded on a FTIR spectrophotometer (FTIR-8400S, Shimadzu, Japan) in the range
of 4000–500 cm–1 using potassium bromide discs.
Isothermal stress testing. – In the IST studies, drug and different excipients (Table II)
were weighed directly into 4 mL glass vials (n = 2) and mixed on a vortex mixer for 2
min. Water (10 %) was added to each of the vials and the drug-excipient blend was fur-
ther mixed with a glass capillary (both ends of which were heat-sealed).
The capillary was broken and left inside the vial to prevent any loss of material.
Each vial was sealed using a teflon-lined screw cap and stored at 50 °C in air oven. The
samples were periodically examined for any unusual color change. After 3 weeks of stora-
ge under the above conditions, samples were quantitatively analyzed using the in-house
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Tonset (°C) Tpeak (°C) Hfcorr (J g–1)a
NTG – 137.21 144.76 91.0346
NTG + lactose 1:2 139.80 143.48 89.4321
NTG + polacrilin K 1:1 138.51 141.78 51.5828
NTG + PVP 1:1 137.58 140.38 31.8860
NTG + talc 3:1 139.63 142.81 40.9006
NTG + Mg-stearate 3:1 – – –
a ÄHfcorr = ÄHfobs/drug conc. in sample (g/100 g).





Control valueb Stressed samplesc
NTG – 100.8 ± 0.7 99.7 ± 2.5
NTG + lactose 1:2 101.4 ± 1.3 100.3 ± 1.7
NTG + polacrilin K 1:1 101.2 ± 2.7 99.8 ± 0.6
NTG + PVP 2:1 101.8 ± 1.4 99.3 ± 1.9
NTG + talc 3:1 100.6 ± 2.7 99.3 ± 2.0
NTG + Mg-stearate 3:1 100.8 ± 1.9 99.1 ± 1.6
a Mean ± standard deviation (n = 3).
b Drug-excipient blends without added water and stored in refrigerator (2 to 8 °C).
c Drug-excipient blends with 10 % (m/m) added water and stored at 50 °C for 3 weeks.
NTG – nateglinide, PVP – polyvinylpryrolidine.
developed HPLC method. Drug-excipient blends without added water stored in a re-
frigerator served as controls.
For sample preparation, 2 mL of methanol was added into each vial. The mixture
was vortexed and transferred to 100-mL volumetric flasks. Vials were rinsed twice with
methanol and the volume made up. The samples were centrifuged and the supernatant
was filtered through a 0.45-µm nylon membrane filter. After appropriate dilutions, sam-
ples were analyzed using HPLC and the drug content was determined from the calibra-
tion curve. A Waters 600 Pump based HPLC system equipped with Waters quaternary
pump, Waters manual injector, Waters on-line degasser AF, CTO-10 AS VP column oven
(at 30 °C) and Waters 2489 UV/Visible detector (detection at 210 nm) was used. Chro-
matographic separation was performed on a C18 Hypersil column, with mobile phase
acetonitrile/phosphate buffer (pH 2.5; 25 mmol L–1) (35:65, V/V; flow rate 1 mLmin–1).
Formulation development and stability study of tablets. – Details of the formulation de-
velopment of the immediate release tablets of NTG are presented in Table III. In brief,
tablets of nateglinide were prepared by wet granulation using a single stroke tablet
punching machine (Hardik Engineering Works, India) fitted with 8-mm standard con-
cave punches. Lactose, drug, Polacrilin K (half of the quantity from Table III) and poly-
vinylpyrrolidone (PVP) were passed through a sieve of 0.177 mm aperture and they
were mixed for 20 min in a polyethylene bag. Granules were prepared by kneading with
ethanol and were kept for air drying in a tray dryer at 45 °C. Dried granules were pas-
sed through a sieve of 0.840-mm aperture to get uniform granules. The another half of
Polacrilin K and talc were passed through a sieve of 0.177-mm aperture and mixed with
the granules for 15 min in a polyethylene bag. Magnesium stearate was passed through
a sieve of 0.177-mm aperture and mixed with the granules for 3 min. Lubricated gra-
nules were compressed into tablets.
The assay of the tablets was carried out as follows. Accurately weighed tablets (n =
6) were dissolved in 100 mL of methanol. The samples were sonicated (Ultra sonic water
bath, Loba Chem, India) for 30 min and then filtered through a nylon membrane filter
(0.45-µm pore size). The filtered solution, after appropriate dilution with methanol, was
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PVP – Polyvinylpyrolidine, IPA – Isopropyl alcohol
analyzed by a validated UV spectroscopic method (11) at 216 nm (UV-1601, Simadzu, Ja-
pan).
Drug release of the tablets (n = 6) was studied using a USP-II dissolution apparatus
(TDT-06T, Electrolab, India) (12) at 50 rpm. Simulated gastric fluid, pH 1.2 plus 0.5 % so-
dium lauryl sulphate (SLS) (900 mL) maintained at 37 ± 0.5 °C was used as dissolution
medium. The samples (10 mL) were withdrawn at predetermined time points (5, 10, 20,
30, 45 and 60 min) and replaced with an equivalent amount of fresh medium. The sam-
ples were filtered through a nylon membrane filter (0.45-µm pore size) and analyzed at
216 nm lmax (11). The cumulative percent drug release was plotted against time to deter-
mine the release profile.
The optimized tablets of NTG were kept in open Petri dishes and stored in a stability
chamber maintained at 40 ± 2 °C and 75 ± 5 % RH (14). The samples were withdrawn pe-
riodically and subjected to the assay and dissolution study.
RESULTS AND DISCUSSION
Drug-excipient compatibility test
DSC and IR. – Selected DSC scans of drug and drug-excipient mixtures are shown
in Figs. 1a-e. Thermal behavior of the pure drug, respective excipient, and the combina-
tion of drug and excipient are compared. The onset temperature of peak (Tonset) (140.21
°C), peak transition temperature (Tpeak) (144.76 °C) and heat of fusion or enthalpy (DHf)
(91.0346 J g–1) of NTG in various excipient mixtures are summarized in Table I.
The DSC thermogram of NTG showed a sharp endothermic peak at 144.76 °C and
peak onset at 140.21 °C. In the majority of cases, the melting endotherm of the drug
(Tonset and Tpeak) was well preserved with slight broadening or shifting towards the
lower temperature range. It has been reported that the shape of the peaks of the DSC
thermogram and enthalpy may change due to the presence of impurity in the materials
used for analysis (5, 6). Thus, changes in the melting endotherm of the drug from 144.76
to 140.38 °C could be due to the mixing of the drug and excipients, which lower the pu-
rity of each component in the mixture and may not necessarily indicate potential incom-
patibility (7, 15, 16).
The DSC thermogram of lactose showed endothermic peaks at 145.29 °C (indicating
dehydration of bound water) and 224.59 °C (melting point). Melting endothermic peak
of NTG lay at 143.48 °C in the NTG-lactose mixture suggesting that there was no interac-
tion between lactose and NTG (Fig. 1a).
The DSC thermogram of polacrilin K showed a broad endotherm at 117.57 °C (start-
ing from 50.80 and ending at 162.63 °C), which may be attributed to the loss of adsorbed
water (6, 16). The thermogram of NTG-polacrilin K mixture (Fig. 1b) showed an endo-
thermic peak of NTG at 141.78 °C, indicating that NTG was compatible with polacrilin K.
In case of PVP, a broad endotherm was observed at 98.43 °C due to loss of adsorbed
moisture (Fig. 1c). The thermogram of the NTG/PVP mixture showed broadening and
shifting of the NTG peak to a lower temperature (140.38 °C). This phenomenon may be
due to simple mixing of the drug with excipient, which lowered the purity of each com-
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ponent (5). This result signifies that NTG and PVP are compatible. In the DSC thermo-
grams of talc, no peaks were observed in the range of 50–300 °C (Fig. 1d). However, the
endothermic peak of NTG was well preserved at 142.81 °C in the DSC thermogram of
the NTG-talc mixture. It was concluded that NTG was compatible with talc.
In the DSC thermogram of magnesium stearate, an endothermic peak was observed
at 98.3 °C with an irregular thermogram. The DSC thermogram of the NTG-magnesium
stearate mixture showed disappearance of the NTG peak (Fig. 1e), which suggested that
there might have been some physical incompatibility between NTG and magnesium
stearate. Therefore, the NTG-magnesium stearate mixture was subjected to IR studies
and its spectrum was compared with the IR spectra of NTG. Characteristic bands of
NTG (Fig. 2a) were observed at 1647 cm–1 (–C=O), 1713 cm–1 (–COOH), 2862–3096 cm–1
(–CH2-cycloalkane) and 3296 cm–1 (–NH stretching). However, the IR spectrum of the
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Mg stearate + NTG
Mg stearate 94.60 °C
Fig. 1. Cont. DSC thermogram of nateglinide with d) talc and e) magnesium stearate.
d)
e)
NTG-magnesium stearate mixture (Fig. 2b) showed the respective characteristic bands
of NTG at 1647, 1712, 2850–2953 (–CH2-cycloalkane) and 3300 cm–1. The results con-
firmed that there was no chemical interaction between NTG and magnesium stearate.
IST. – Lactose, polacrilin K, PVP and talc were used for the formulation of immediate
release tablets of NTG as a diluent, superdisintegrant, binder and lubricant, respectively,
based on the results of DSC thermograms and IR spectra. The drug-excipient mixtures
were tested using the IST technique and the quantitative results are shown in Table II.
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However, as seen from Table II, there was less than 1% change in the drug concen-
tration in IST samples after 3 weeks of storage under stressed conditions.
Moreover, when the HPLC chromatogram of the mixture of NTG and individual ex-
cipients was compared with that of pure NTG during the IST sample analysis, it was
found that the retention time (9.61 min) and the shape of the NTG peak remained un-
changed. Hence, it was concluded that NTG and the excipients used were compatible.
In case of the NTG-magnesium stearate mixture, no definite conclusion could be
drawn based on the DSC results alone. However, the results of IST studies showed that
the residual drug concentration was within the set limits and the characteristic bands of
NTG were well preserved in the IR spectrum of NTG-magnesium strearate mixture, con-
firming their compatibility.
Formulation development and stability study
The tablets were evaluated after 3 months of storage under accelerated stability con-
ditions (40 ± 2 °C and 75 ± 5 % RH), the results of which are presented in Table IV. It is
evident that the formulation is stable in terms of drug concentration, disintegration time
(DT) and time required to release 85 % (m/m) of the drug (t85). There was a change in the
drug concentration of < 2 %, DT < 1 s and t85 < 0.75 min after 3 months of storage under
accelerated stability conditions, leading to the conclusion that the immediate release tab-
lets of NTG were stable after storage under accelerated stability conditions.
CONCLUSIONS
The results of the studies confirmed that DSC and IR could be used as rapid meth-
ods to evaluate the compatibility between NTG and excipients. However, the isothermal
stress testing techniques after storage of the mixture of NTG and individual excipient
should also be adopted in conjunction with DSC and IR studies to reach a definite con-
clusion. In the present study, the DSC analysis along with IR spectroscopy and HPLC
analysis (for IST studies) were successfully employed to assess the compatibility of NTG
with the excipients used in the development of immediate release tablet formulations.
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1 month 2 months 3 months
Drug concentration remained (%)a 99.6 ± 2.4 99.30 ± 2.8 98.9 ± 3.4 98.50 ± 2.5
Hardness (kg cm–2) 5.00 ± 0.23 5.00 ± 1.32 5.00 ± 1.27 5.00 ± 1.63
DT (s)a 32.14 ± 1.57 36.21 ± 1.88 44.32 ± 2.24 46.11 ± 2.33
t85 (min)a 14.76 ± 2.19 15.43 ± 1.26 15.28 ± 1.20 15.27 ± 1.82
t85 time required to release 85 % (m/m) of the drug.
a Mean ± standard deviation (n = 3).
DT – disintegration time.
From the results of the DSC studies an interaction was suspected between NTG and
magnesium stearate. However, based on the results of IR spectroscopy and IST study,
the possibility of incompatibility between NTG and magnesium stearate was ruled out.
Therefore, no definite evidence of interaction was observed between NTG and the ex-
cipients used in the development of in-house formulations of immediate release tablets
of NTG. Based on probable compatibility of the excipients with NTG confirmed by the
methods described above, formulations of immediate release tablets of NTG were deve-
loped using the excipients studied.
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S A @ E T A K
Ispitivanje kompatibilnosti nateglinida s pomo}nim tvarima u razvoju tableta
nateglinida za trenutno osloba|anje
NIHAR RANJAN PANI, LILA KANTA NATH i SUJATA ACHARYA
Koriste}i termi~ke metode kao {to su diferencijalna pretra`na kalorimetrija (DSC) i
infra-crvena spektrofotometrija (IR), te izotermi~ka stres-testiranja (IST) ispitana je kom-
patibilnost nateglinida s izabranim ekscipiensima u razvoju tableta nateglinida za tre-
nutno osloba|anje. Rezultati DSC ispitivanja pokazala su da magnezijev stearat stupa u
odre|enu interakciju s nateglinidom. Me|utim, IR i IST ispitivanja pokazuju da su svi
upotrijebljeni ekscipiensi kompatibilni s nateglinidom. Optimirana formulacija bila je
stabilna preko 3 mjeseca u testovima ubrzanog starenja (40 ± 2 °C i 75 ± 5 % RH). Kom-
patibilnost ekscipiensa s nateglinidom uspje{no je evaluirana koriste}i kombinaciju ter-
mi~ke i IST metode, a formulacije razvijene koriste}i kompatibilne ekscipiense bile su
stabilne.
Klju~ne rije~i: nateglinid, tableta za trenutno osloba|anje, inerakcije lijek-ekscipiens
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